Drug Search Results

Adrabetadex

Alternative Names: adrabetadex, vts-270, vts270, vts 270
Latest Update: 2024-01-17
Latest Update Note: Clinical Trial Update

Product Description

to Treat Niemann-Pick Type C1 (NPC1) Disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04958642)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mallinckrodt
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Niemann-Pick Disease, Type C|Niemann-Pick Diseases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2015-002548-15	P3	Completed	Niemann-Pick Disease, Type C\|Niemann-Pick Diseases	2022-04-11

Recent News Events

Date	Type	Title
07/01/2023	PubMed	Low Risk Profile of Long-Term Repeated Lumbar Puncture for Intrathecal Delivery of 2-Hydroxypropyl-Beta-Cyclodextrin in Patients With Niemann-Pick Type C.
06/16/2023	News Article	International Niemann-Pick Disease Registry and Mandos Health announce new research collaboration using real-world data to evaluate the treatment effects of VTS-270 to manage Niemann-Pick type C1
03/01/2023	PubMed	Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1.
02/01/2022	PubMed	Consistently High Agreement Between Independent Raters of Niemann-Pick Type C1 Clinical Severity Scale in Phase 2/3 Trial.
07/01/2021	News Article	Mandos, LLC Completes Acquisition of Adrabetadex from Mallinckrodt Pharmaceuticals
05/19/2021	News Article	Mandos, LLC Agrees to Acquire Adrabetadex from Mallinckrodt Pharmaceuticals
02/28/2021	News Article	FIREFLY FUND HOSTS INAUGURAL RUN FOR RARE

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions